Previous Page
11-05 :: May/June 2011
nanotimes
Companies Facts
AMRI also will receive royalties on worldwide sales of any commercialized compounds. http://www.amriglobal.com/
ting of patents for an application system, which for the first time allows long-term and outpatient admi- nistration of therapeutic substances into brain tissue using the so-called Convection Enhanced Delivery (CED).
A B http://www.antisense-pharma.com
erkeley Design Automation Inc., provider of the Analog FastSPICE™ unified circuit verification
platform announced that Mohagi, a developer of energy-efficient analog and mixed-signal IP, has se- lected the company‘s Analog FastSPICE Nano SPICE simulator (AFS Nano) for analog and mixed-signal IP verification. Priced at $1,900 for a 1-year time- based license, AFS Nano is up to 10x faster than traditional SPICE, is foundry certified down to 28nm, and supports up to 5,000 element circuits.
Berkeley Design Automation, Inc. (BDA) is the reco- gnized leader in advanced analog, mixed-signal, and RF (AMS/RF) verification. The BDA Analog FastSPICE unified circuit verification platform (AFS Platform) combines the accuracy, performance, and capacity needed to verify GHz designs in nanometer-scale silicon.
io-Gate AG (ISIN: DE000BGAG999), a German provider of antimicrobial products and multifunc-
ntisense Pharma GmbH, a biopharmaceutical company in Germany, has announced the gran-
tional surfaces for medical applications, announced the resignation of Dr Michael Wagener from his position on the Board of Management for personal reasons. His duties will be restructured at executive level.
Furthermore, the company published the results for 2010. Sales increased by 50% to EUR3,099,000. The loss clearly decreaed to EUR1,622,000 (2009: EUR2,614,000). As of balance sheet day (31.12.) the equity ratio increased to 70% from 62% in 2009. http://www.bio-gate.de
B
iotage (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal
chemistry, announced a collaborative research ag- reement with The Laboratory of Peptide & Protein Chemistry & Biology (PeptLab) located in Florence, Italy. The renowned peptide research facility, led by Professor Anna Maria Papini, has agreed to contri- bute technical input towards the future development of Biotage related products as well as provide trai- ning facilities for demonstrating Biotage’s range of peptide synthesis, purification and resin products.
PeptLab is an interdepartmental structure of the University of Florence, located at the Polo Scientifico e Tecnologico in Sesto Fiorentino, founded in 2004 by Professor Paolo Rovero (Dept. of Pharmaceutical Sciences), Professor Anna Maria Papini and Dr. Ma- rio Chelli (Dept. of Organic Chemistry ‘Ugo Schiff’), and Professor Francesco Lolli (Dept. of Neurological Sciences). http://www.biotage.com
http://www.unifi.it/peptlab/PeptLab/index_en.html
19